Docoh
Loading...
Sign up Log in

ILMN Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Company profile

Ticker
ILMN
Exchange
NASDAQ
Website
www.illumina.com
CEO
Francis deSouza
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Jan 02
Sector
Manufacturing > Analytical Laboratory Instrument Manufacturing
Industry (SIC)
Laboratory Analytical Instruments
Agilent • Bio-Rad Laboratories • Avantor • Waters • Bruker • Coherent • Mettler-Toledo International • Pacific Biosciences of California • Harvard Bioscience • 10x Genomics ...
Former names
ILLUMINA INC
SEC CIK
0001110803
Corporate docs
IRS number
330804655

ILMN stock data

(
)

News

Pro users get this 30m faster
Ginkgo Bioworks, Which Prints DNA And Creates Genetically Modified Food, Exploring SPAC Deal: Report
9 Apr 21
One of the largest SPACs seeking a target could be nearing a $20 billion deal to bring one of the largest privately-held biotechnology companies public.
51 Biggest Movers From Yesterday
7 Apr 21
Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share.
P/E Ratio Insights for Illumina
6 Apr 21
33 Stocks Moving In Tuesday's Mid-Day Session
6 Apr 21
Wells Fargo Maintains Underweight on Illumina, Raises Price Target to $330
6 Apr 21

Press releases

Pro users get this 30m faster
IDbyDNA Shares Insights on Role of Metagenomics for Tracking COVID-19 on New Illumina Podcast
9 Apr 21
SAN FRANCISCO, April 9, 2021 /PRNewswire-PRWeb/ -- Today, IDbyDNA, the company revolutionizing the use of metagenomics to improve health by decoding the unknown, is being featured on two episodes of the new Illumina,
IDbyDNA Shares Insights on Role of Metagenomics for Tracking COVID-19 on New Illumina Podcast
9 Apr 21
Metagenomics Innovator Featured on New Series about Role of Genomics for Managing Global Pandemics SAN FRANCISCO (PRWEB) April 09, 2021 Today, IDbyDNA, the company revolutionizing the use of metagenomics to improve
Thinking about trading options or stock in Illumina, BP, General Motors, Norwegian Cruise Line, or Wynn Resorts?
6 Apr 21
NEW YORK, April 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ILMN, BP, GM, NCLH, and WYNN.
Quantitative Scientific Solutions Joins DNA Storage Alliance
6 Apr 21
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
5 Apr 21

Calendar

16 Feb 21
18 Apr 21
2 Jan 22

Financial summary

Financial statements Chart ILMN financial data
Quarter (USD)
 Jan 21 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Jan 21 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Illumina earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.81B 1.81B 1.81B 1.81B 1.81B 1.81B
Cash burn (monthly) (positive/no burn) 19.33M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a 67.82M n/a n/a n/a n/a
Cash remaining n/a 1.74B n/a n/a n/a n/a
Runway (months of cash) n/a 90.1 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Recent insider trades

ILMN insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
6 Apr 21 Jay T Flatley Common Stock Sell Dispose S No Yes 423.435 4,000 1.69M 160,933
6 Apr 21 Tousi Susan H Common Stock Sell Dispose S No Yes 423.435 500 211.72K 44,143
5 Apr 21 Tousi Susan H Common Stock Sell Dispose S No Yes 386.03 300 115.81K 44,643
5 Apr 21 Febbo Phillip G. Common Stock Payment of exercise Dispose F No No 384.54 131 50.37K 5,461
22 Mar 21 Charles Dadswell Common Stock Sell Dispose S No Yes 416.24 314 130.7K 6,832
16 Mar 21 Jay T Flatley Common Stock Sell Dispose S No Yes 421.06 4,000 1.68M 164,933
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

ILMN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

91.4% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 960 876 +9.6%
Opened positions 167 99 +68.7%
Closed positions 83 95 -12.6%
Increased positions 352 358 -1.7%
Reduced positions 312 299 +4.3%
13F shares
 Current Prev Q Change
Total value 49.34B 43.36B +13.8%
Total shares 133.38M 131.92M +1.1%
Total puts 1.38M 1.74M -20.7%
Total calls 1.28M 1.55M -17.5%
Total put/call ratio 1.1 1.1 -3.9%
Largest owners
 Shares Value Change
Baillie Gifford & Co 19.83M $7.34B +11.9%
Vanguard 11.33M $4.19B -1.3%
BLK Blackrock 11.25M $4.16B -4.2%
Edgewood Management 6.95M $2.57B -2.9%
STT State Street 5.88M $2.18B -3.7%
BK Bank Of New York Mellon 3.7M $1.37B +13.5%
Loomis Sayles & Co L P 3.5M $1.3B -0.0%
Sands Capital Management 2.95M $1.09B -4.1%
MS Morgan Stanley 2.86M $1.06B +9.1%
JHG Janus Henderson 2.74M $1.01B +332.7%
Largest transactions
 Shares Bought/sold Change
Baillie Gifford & Co 19.83M +2.11M +11.9%
JHG Janus Henderson 2.74M +2.11M +332.7%
Polen Capital Management 2.33M +1.77M +313.7%
Norges Bank 1.55M +1.55M NEW
Massachusetts Financial Services 454.49K -1.1M -70.8%
Capital World Investors 1.52M -1.1M -42.0%
American Century Companies 144.48K -971.22K -87.1%
ARK Investment Management 50.59K -928.08K -94.8%
Generation Investment Management 1.96M +784.34K +66.5%
Select Equity 505.44K -670.1K -57.0%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Thermo Fisher Scientific • Roche Holding • Luminex • Biocept • Agilent • Caredx • Pacific Biosciences of California • Vyant Bio • Veracyte • Nanostring
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: advisory, Altera, APAC, Arnold, attestation, Bank, behavioral, Bluebee, bridge, bring, cBot, certainty, certiorari, Chinese, CircLigase, citizen, climate, collar, Commissioner, consumption, contemplated, COVIDSeq, csr, culture, curate, decide, decree, deep, depart, departing, depressing, desire, divest, duration, embed, EMEA, Enancio, enjoining, entry, EPS, extreme, FastTrack, feel, FGx, footnote, forma, foster, gas, Goldman, great, greenhouse, GRI, healthy, inaccurate, inclusion, ineffective, invocation, jeopardize, KAREN, letter, leverage, lieu, loan, LP, mission, morale, motivate, Northstar, opportunity, organizational, pandemic, pendency, permanent, persistent, petition, pipeline, pro, promulgated, rata, Remote, remotely, renegotiate, Renminbi, replace, restraining, restraint, SASB, spread, steward, stewardship, Supreme, surviving, talent, Task, TCFD, threat, thrive, travel, unavailable, USA, voluntary, waived, waste, water, women, Yuan
Removed: accurate, billing, BlueFish, bona, breached, build, construction, CSPro, deterioration, discrete, Durascript, efficiency, efficiently, fide, financed, fulfillment, group, immaterial, interface, judged, lacked, landlord, malfunction, mentioned, October, offered, partnered, perpetual, pretax, principle, promised, proper, prospectively, provisional, pursue, pursuit, resource, retrospectively, revaluing, rounded, selected, setup, step, unaudited, unrelated, visibility
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
16 Feb 21
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
30 Apr 20
10-K
2019 FY
Annual report
10 Feb 20
10-Q
2019 Q3
Quarterly report
24 Oct 19
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
25 Apr 19
10-K
2018 FY
Annual report
11 Feb 19
10-Q
2018 Q3
Quarterly report
23 Oct 18

Current reports

View all
8-K
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
5 Apr 21
8-K
Other Events
22 Mar 21
8-K
Illumina Announces Board Changes
18 Mar 21
8-K
Other Events
16 Mar 21
8-K
Index to Consolidated Financial Statements
12 Mar 21
8-K
Entry into a Material Definitive Agreement
8 Mar 21
8-K
Other Events
4 Mar 21
8-K
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020
11 Feb 21
8-K
Entry into a Material Definitive Agreement
5 Feb 21
8-K
Results of Operations and Financial Condition
12 Jan 21

Registration and prospectus

View all
425
Business combination disclosure
29 Mar 21
424B2
Prospectus for primary offering
17 Mar 21
FWP
Free writing prospectus
16 Mar 21
425
Business combination disclosure
16 Mar 21
424B2
Prospectus for primary offering
16 Mar 21
425
Business combination disclosure
12 Mar 21
S-3ASR
Automatic shelf registration
12 Mar 21
425
Business combination disclosure
4 Mar 21
424B5
Prospectus supplement for primary offering
4 Mar 21
S-4MEF
Addition of securities to prior registration
4 Mar 21

Proxies

View all
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DEF 14A
Definitive proxy
16 Apr 21
DEFA14A
Additional proxy soliciting materials
16 Apr 20
DEF 14A
Definitive proxy
16 Apr 20
DEFA14A
Additional proxy soliciting materials
24 May 19
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
PRE 14A
Preliminary proxy
25 Mar 19
DFAN14A
Additional proxy materials by non-management
5 Nov 18
DFAN14A
Additional proxy materials by non-management
2 Nov 18

Other

View all
EFFECT
Notice of effectiveness
10 Feb 21
CORRESP
Correspondence with SEC
4 Feb 21
UPLOAD
Letter from SEC
2 Dec 20
SD
Conflict minerals disclosure
20 May 20
SD
Conflict minerals disclosure
13 May 19
SD
Conflict minerals disclosure
30 May 18
CT ORDER
Confidential treatment order
8 Mar 18
SD
Conflict minerals disclosure
4 Jun 17
NO ACT
No action letter
24 Jan 17
SD
Conflict minerals disclosure
24 May 16

Ownership

View all
4
ILLUMINA / JAY T FLATLEY ownership change
7 Apr 21
4
ILLUMINA / Phillip G. Febbo ownership change
7 Apr 21
4
ILLUMINA / SUSAN H TOUSI ownership change
7 Apr 21
4
ILLUMINA / Charles Dadswell ownership change
24 Mar 21
4
ILLUMINA / JAY T FLATLEY ownership change
18 Mar 21
4
ILLUMINA / SUSAN H TOUSI ownership change
9 Mar 21
SC 13G/A
Twist Bioscience / ILLUMINA ownership change
8 Mar 21
4
ILLUMINA / JAY T FLATLEY ownership change
4 Mar 21
4
ILLUMINA / KAREN K MCGINNIS ownership change
22 Feb 21
4
ILLUMINA / JAY T FLATLEY ownership change
18 Feb 21

Patents

View all
GRANT
Utility
Catalyst-free surface functionalization and polymer grafting
13 Apr 21
The present application relates to a method for preparing a functionalized surface and the use in DNA sequencing and other diagnostic applications.
GRANT
Utility
Nucleic acid sequence analysis from single cells
13 Apr 21
Presented herein are methods and compositions for multiplexed single cell gene expression analysis.
GRANT
Utility
System and methods for selective effluent collection
13 Apr 21
A system may include a flow cell through which a plurality of reagents may be pumped during a genetic sequencing operation, an effluent line that, in operation, is to conduct a used reagent, a used reagent valve to receive the used reagent from the effluent line and controllable to select one of a plurality of disposal paths for the used reagent, and control circuitry coupled to the used reagent valve that, in operation, is to control the used reagent valve to select a desired one of the disposal paths depending upon which reagent is being pumped though the flow cell.
GRANT
Utility
In-line pressure accumulator and flow-control system for biological or chemical assays
13 Apr 21
Flow-control system includes a fluid reservoir configured to store a fluid, a pressure accumulator in flow communication with and positioned downstream from the fluid reservoir, and a loading zone that is configured to receive and fluidly couple to a flow cell having a biological or chemical sample.
APP
Utility
High-throughput Single-cell Transcriptome Libraries and Methods of Making and of Using
8 Apr 21
Provided herein are methods for preparing a sequencing library that includes nucleic acids from a plurality of single cells.

Transcripts

View all
2020 Q4
Earnings call transcript
12 Feb 21
2020 Q3
Earnings call transcript
29 Oct 20
2020 Q2
Earnings call transcript
7 Aug 20
2020 Q1
Earnings call transcript
30 Apr 20
2019 Q4
Earnings call transcript
29 Jan 20
2019 Q3
Earnings call transcript
25 Oct 19
2019 Q2
Earnings call transcript
29 Jul 19
2019 Q1
Earnings call transcript
25 Apr 19
2018 Q4
Earnings call transcript
29 Jan 19
2018 Q3
Earnings call transcript
24 Oct 18

Reddit threads

View all